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See Article, pages 549–556The issue of whether the hepatitis C virus (HCV) affects brain
function continues to arouse interest, investigation, and debate.
Symptoms such as fatigue, poor memory, and concentration
(‘‘brain fog’’) are commonplace and an effect of this infection on
mental health related quality of life, which is independent of liver
ﬁbrosis, is well established [1]. However, despite convergent lines
of evidence pointing to a biological effect of HCV within the CNS
and some hypothesised mechanisms, there remains, as yet, a lack
of incontrovertible evidence to deﬁnitively prove the fact. Paral-
lels with HIV infection are commonly drawn, where AIDS related
dementia is now rare with highly active anti-retroviral therapy
(HAART) but milder neurocognitive impairments can persist
despite immune reconstitution and viral suppression [2]. A degen-
erative brain process is not seen in HCV monoinfection and there
remains doubt in the hepatology community as to whether HCV is
a virus that can trigger neurological dysfunction. Furthermore,
there does not appear to be a clinical consensus as to whether
the relatively mild neurocognitive symptoms in HCV infection
represent a signiﬁcant or important element of the disease.
The possibility of a cerebral effect of HCV was raised ten years
ago with the publication of proton magnetic resonance spectros-
copy (MRS) and neuropsychological data, which showed evidence
of altered cerebral metabolism and cognitive impairment in
patients without advanced liver disease [3–5]. A number of fur-
ther imaging studies, using MRS [6,7], positron emission tomog-
raphy (PET) and single-photon emission computed tomography
(SPECT) [8] in patients without cirrhosis have demonstrated met-
abolic and neurochemical brain abnormalities, which differ to
those described in hepatic encephalopathy. Rather, the ﬁndings
suggest an inﬂammatory state within the brain with altered sero-
tonergic and dopaminergic neurotransmission. In particular,
elevated basal ganglia and white matter choline (Cho) and
myo-inositol (mI), measured with proton MRS and often reported
relative to creatine (Cr), are consistent with glial cell activation
and proliferation and parallel changes observed in cerebral HIV
infection [9,10]. Reduced N-acetylaspartate (NAA) has also been
reported in HIV and HCV monoinfections [6,7].
Agreaternumberof reportshavedocumentedmildbutmeasure-
able cognitive deﬁcits in patients with HCV infection, which are not
readily accounted for by the severity of liver disease, associated rec-
reational drug use or other potential confounding factors [11].Journal of Hepatology 20
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confounders were excluded or controlled for and in terms of their
cognitive assessment methodology, there is a reported pattern of
deﬁcits in attention, working memory and learning ability with
increased reaction times and relatively preserved accuracy. The
prevalence of depression and anxiety was high in these reports but
there donot appear tobe clear associationsbetween affective symp-
toms and cognitive function. However, fatigue, perhaps the com-
monest symptom in HCV infection, was reported to be associated
with worse cognitive performance [6].
Despite the increasing body of descriptive literature, there are
very few longitudinal reports of the effect of treatment and, in
particular, of the effect of successful viral clearance on brain
metabolism [12]. It is in this context that the small pilot study
from Byrnes and colleagues, published in the current issue, is
welcome [13]. Large treatment studies have demonstrated an
improvement in HRQL and fatigue after a sustained virological
response (SVR) to pegylated interferon and ribavirin but these
studies have not generally blinded their subjects to treatment
outcome and the knowledge of a ‘‘cure’’ is highly likely to skew
results [14]. If the hypothesis to be tested were that a cerebral
abnormality is due to HCV itself, objective demonstration of an
improvement of that abnormality after SVR would be highly sup-
portive of the hypothesis. Byrnes and colleagues report their ﬁnd-
ings in a small patient cohort which was studied with proton
MRS and cognitive assessment before, during and after standard
antiviral treatment with pegylated interferon and ribavirin. A
second group of untreated patients was also studied at two time
points. Overall, there were no signiﬁcant changes in cerebral MRS
during and after antiviral treatment. However, a sub-group anal-
ysis of viral responders and non-responders showed signiﬁcant
metabolic changes over time in the responder group only, consis-
tent with normalisation of the metabolites, previously reported
as elevated in HCV infection [9,10]. Signiﬁcant reductions were
observed in basal ganglia Cho/Cr and mI/Cr ratios in SVRs
(n = 8) but not in non-responders or relapsers (n = 6). The authors
interpret this as an improvement in cerebral immune activation
in those who cleared the virus. Patients in the treated and
untreated groups tended to show an improvement in cognitive
function over time, which was ascribed to a practice effect on
the cognitive battery. However, when responders and non-
responders were compared again, SVRs demonstrated signiﬁcant
improvements in verbal learning, memory, and visuospatial
memory, which were not seen in the non-responders.12 vol. 56 j 513–514
Editorial
This study is important because it is the ﬁrst to demonstrate
that successful clearance of HCV infection can result in changes
in cerebralmetabolism thatmay underlie improvements in neuro-
cognitive performance. The obviousweakness in this paper, which
limits the conclusions that can be drawn at this time, is the small
sample size. The signiﬁcant ﬁndings are only seen in a sub-group
analysis, with very small groups. It is possible that a treatment
effect was not seen in the non-responders because of a type II
error. Furthermore, the absence of a healthy control group pre-
vents conclusions about the importance of the observed changes.
In a study published this year, Pattullo and colleagues also used
MRS to assess the effect of SVR on brain metabolism [12]. In a lar-
ger study of 40 patients (31 SVRs and 9 non-responders) signiﬁ-
cant increases in globus pallidus Cho/Cr and NAA/Cr were seen
in SVRs after treatment compared to baseline. These changes were
not associated with cognitive measures, which did not improve
with viral eradication. The opposite effect of viral eradication on
Cho/Cr in the report from Byrne and colleagues is not readily
explained but may be related to different patient characteristics,
voxel position and acquisition parameters. Pattullo does however
report reductions in globus pallidus NAA/Cr at baseline compared
to controls, which increased signiﬁcantly in the SVRs. Despite this,
the authors concluded that when all other causes for cerebral dys-
function are excluded, viral clearance does not contribute to sig-
niﬁcant changes in brain function or biochemistry.
There are a number of strands of evidence, in addition to clin-
ical data, that support a biological effect of HCV on the brain.
Positive and negative strand HCV genetic sequences have been
ampliﬁed from RNA extracted from human post-mortem brain
samples and quasispecies analyses suggest replication within
the CNS, albeit at a low level [15,16]. Immunohistochemical
staining for HCV non-structural protein 3 (NS3) in brain tissue
suggests that astrocytes and microglia might be the host cell
for HCV infection [17]. Gene expression analysis in laser dissected
microglia, which stained with antibodies against HCV NS3,
revealed up-regulation of proinﬂammatory genes such as TNF
alpha and IL-1b that was not seen in NS3ve microglia or in cells
from HCVve individuals [18]. There are emerging in vitro data to
support neuroimmune activation by HCV [19] and a recent report
demonstrated that a human neuroepithelioma cell line expressed
HCV entry receptors and allowed productive infection by the JFH-
1 HCV strain, being the ﬁrst non-hepatocyte line to do so [20].
These studies lead to the hypothesis that certain HCV variants
or strains may gain entry to the CNS in susceptible individuals, to
replicate at low but sufﬁcient levels to cause immune activation
of resident microglia, triggering established pathways that result
in neuronal dysfunction [21]. In this hypothesis, successful viral
eradication might reverse or attenuate the process, as suggested
by the preliminary data from Byrnes and colleagues. If this is the
case, it will be of interest to discover whether the evolving inter-
feron-free regimes of direct acting anti-virals have the same
effect or whether neurocognitive impairments could persist as
in the case of HAART for HIV infection. Alternatively, one might
consider that eradication of HCV from the liver results in normal-
isation of a chronic low-level inﬂammatory state, with concomi-
tant improvements in brain function and metabolism secondary
to a reduction of abnormal signalling, possibly by cytokines, from
the periphery across the blood brain barrier.
The pilot study fromByrnes and colleagues is small but it serves
to re-energise the debate as to whether there is a virological effect
of HCV on brain function. A better knowledge of this is important514 Journal of Hepatology 201for our understanding of the natural history of this infection and
the symptoms it causes and for our ability to design appropriate
therapeutic regimes. Further large studies are now indicated to
determine whether successful antiviral treatment is deﬁnitively
associatedwith improvements in brain biochemistry and function.
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